Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 3430-23-7 | MDL No. : | MFCD00128859 |
Formula : | C6H5Br2N | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BNCGUATWCKZLLN-UHFFFAOYSA-N |
M.W : | 250.92 | Pubchem ID : | 819338 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.6 |
TPSA : | 12.89 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.98 cm/s |
Log Po/w (iLOGP) : | 2.16 |
Log Po/w (XLOGP3) : | 2.6 |
Log Po/w (WLOGP) : | 2.92 |
Log Po/w (MLOGP) : | 2.33 |
Log Po/w (SILICOS-IT) : | 3.18 |
Consensus Log Po/w : | 2.64 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.53 |
Solubility : | 0.0746 mg/ml ; 0.000297 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.52 |
Solubility : | 0.758 mg/ml ; 0.00302 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.12 |
Solubility : | 0.019 mg/ml ; 0.0000757 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.39 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362+P364-P403+P233-P501 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
72% | Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -100℃; for 0.0833333 h; Stage #2: at -100 - -78℃; for 1.33333 h; Stage #3: With ammonium chloride In tetrahydrofuran; hexane; waterSaturated solution |
(a) Intermediate 1a: δ-Bromo^-methyl-pyridine-S-carbaldehyde:; 3,5-Dibromo-4-methyl-pyridine (3.8 g, 15.1 mmol) C1 was stirred in dry THF (150 mL) at -1000C(N2/ether) under argon. n-Butyllithium (2.5 M in hexanes, 6.2 mL, 15.4 mmol) was added dropwise, and the reaction stirred for 5 minutes DMF (1.8 mL, 23.2 mmol) was added, and the reaction was stirred for 20 minutes at -100 0C and then for 1 hour at -78 0C. The reaction was quenched with sat. NH4CI and extracted with ether. Organics were washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by silica gel chromatography (20percent ethyl acetate/hexanes) gave 2.18 g (72percent) of intermediate 1a as a clear oil which slowly solidified. 1H NMR (300 MHz, CDCI3) δ 10.25 (s, 1 H), 8.84 (s, 1H), 8.83 (s, 1H), 2.76 (s, 3H). Anal. (C7H6BrNO) C, H, N. |
[ 29976-20-3 ]
3,5-Dibromo-2,4-dimethylpyridine
Similarity: 0.92
[ 3430-25-9 ]
2,3,5-Tribromo-4-methylpyridine
Similarity: 0.88
[ 29976-20-3 ]
3,5-Dibromo-2,4-dimethylpyridine
Similarity: 0.92
[ 3430-25-9 ]
2,3,5-Tribromo-4-methylpyridine
Similarity: 0.88